KB001

Targets a Pseudomonas aeruginosa virulence factor

Phase of research

Phase Two Clinical Trial

How it helps

Anti-Inflammatory

General information

KB001 is an investigational substance used in studies and not yet available as a human pharmaceutical. It is being developed by KaloBios as a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated patients. In relation to cystic fibrosis, our AIM tool found the data that KB001 can help cystic fibrosis patients with Pseudomonas aeruginosa infection.

KB001 on DrugBank

Synonyms

N/A

Marketed as

Dietary sources

N/A

Structure image not available

N/A

Drug-Mutation Relation

results for 1677delTA / 2711delT

See all data on KB001

Treats

Mutation	Link	Tested on	Impact factor	Notes
General effect	Safety Study of KB001 in People with CF and Pseudomonas aeruginosa (Kalobios KB001-03)	humans	N/A
General effect	KB001-A in people with CF and Pseudomonas aeruginosa (KaloBios KB001-05)	humans	3.86	Minor effect.

Does not treat

Mutation	Link	Tested on	Impact factor	Notes